Hypothyroidism in pregnancy: first trimester, fetal effects, and clinical significance
Why the first trimester matters most
During the first trimester, the fetus is almost entirely dependent on maternal thyroid hormone, especially thyroxine (T4).
The fetal thyroid gland does not become functionally active until around 12–14 weeks of gestation, and even then maternal hormone continues to contribute significantly throughout pregnancy.
Thyroid hormones are essential for:
• Fetal brain and nervous system development
• Neuronal migration and myelination
• Growth and skeletal maturation
• Placental function and pregnancy maintenance
Types of hypothyroidism in pregnancy
1. Overt hypothyroidism
• Elevated TSH above the pregnancy-specific range
• Low free T4
This is the more serious form and clearly associated with adverse outcomes.
2. Subclinical hypothyroidism
• Elevated TSH
• Normal free T4
This is milder and more common. The degree of fetal risk is smaller and sometimes controversial, but treatment is often recommended in pregnancy.
3. Isolated hypothyroxinemia
• Normal TSH
• Low free T4
Typical first-trimester TSH target: Approximately 0.1–2.5 mIU/L
Maternal effects of hypothyroidism in the first trimester
Untreated hypothyroidism increases the risk of:
• Fatigue, weight gain, constipation, cold intolerance
• Anemia
• Miscarriage
• Hyperemesis gravidarum (sometimes associated)
• Preeclampsia and gestational hypertension
• Placental abruption
• Postpartum hemorrhage
• Preterm delivery
• Impaired fertility and recurrent pregnancy loss
Fetal and neonatal effects
1. Neurodevelopmental effects (most important)
Maternal T4 is critical for fetal brain development in the first trimester. Severe untreated hypothyroidism can lead to:
• Reduced IQ in the child
• Impaired cognitive function
• Developmental delay
• Learning difficulties
• Motor and language delays
Historically, severe iodine deficiency and untreated hypothyroidism were associated with cretinism, characterized by profound intellectual disability, deafness, and motor abnormalities.
For milder or subclinical hypothyroidism, the effect on neurodevelopment is less consistent across studies, but some evidence suggests subtle reductions in cognitive performance.
2. Fetal growth and pregnancy outcomes
Hypothyroidism can increase the risk of:
• Intrauterine growth restriction (IUGR)
• Low birth weight
• Preterm birth
• Stillbirth (rare, usually with severe untreated disease)
• Fetal distress
• NICU admission
3. Congenital hypothyroidism in the fetus/newborn
Maternal hypothyroidism does not usually cause permanent congenital hypothyroidism in the baby, because most cases are due to fetal thyroid dysgenesis or dyshormonogenesis.
However:
• Maternal iodine deficiency or blocking antibodies can affect fetal thyroid function.
• Babies of mothers with autoimmune thyroid disease may have transient thyroid dysfunction.
Newborn screening is important because congenital hypothyroidism is treatable if detected early.
How significant is hypothyroidism in the first trimester? - significance depends on severity and timing.
Overt hypothyroidism: highly significant
This is clearly associated with increased maternal and fetal morbidity.
Untreated overt hypothyroidism in early pregnancy can have lasting effects on the child’s neurodevelopment and increases the risk of miscarriage and obstetric complications.
Subclinical hypothyroidism: moderately significant
The risks are smaller and evidence is mixed, but many guidelines recommend treatment because:
• Levothyroxine is safe in pregnancy
• Treatment may reduce miscarriage and preterm birth in some women
• Potential neurodevelopmental benefits are possible
Mild TSH elevations: often less significant
A slightly elevated TSH with normal free T4 and no thyroid antibodies may have minimal clinical impact, but close monitoring is still important.
Autoimmune thyroid disease and antibodies
Thyroid peroxidase (TPO) antibodies are important because:
• TPO-positive women have a higher risk of miscarriage and preterm birth even if thyroid function is normal.
• They are more likely to develop hypothyroidism during pregnancy.
When is treatment recommended?
• Overt hypothyroidism
• Subclinical hypothyroidism with TSH above the pregnancy-specific upper limit, especially if TPO antibodies are positive
• Women with prior thyroid disease or infertility/recurrent pregnancy loss may be treated at lower thresholds
Prognosis
When diagnosed early and treated appropriately:
• Most women have normal pregnancies.
• Fetal outcomes are generally excellent.
• Neurodevelopmental risks are greatly reduced.
The greatest concern is untreated or poorly controlled overt hypothyroidism in the first trimester, because this is the period of rapid fetal brain development.
Even when hypothyroidism is diagnosed in the first trimester, the standard approach is prompt treatment with levothyroxine, not pregnancy termination.
• Most women with hypothyroidism who receive appropriate treatment go on to have healthy pregnancies and healthy children.
• The risks to the fetus are generally increased probabilities of adverse outcomes (miscarriage, preterm birth, lower neurocognitive performance), not predictable or inevitable fetal abnormalities.
• There is no specific congenital malformation pattern that would allow clinicians to determine that a fetus has been irreversibly affected solely because the mother was hypothyroid.
What about severe untreated hypothyroidism?
Even severe overt hypothyroidism:
• Increases the risk of miscarriage, fetal growth restriction, preeclampsia, and neurodevelopmental impairment.
• Does not constitute a fetal anomaly or lethal condition that would justify termination on fetal grounds.
When might termination be considered?
Termination would be based on:
• Major fetal structural abnormalities detected on ultrasound.
• Confirmed severe genetic disorders.
• Maternal conditions posing serious threats to maternal life or health.
In counseling terms
If a woman presents at 8–12 weeks with newly diagnosed overt hypothyroidism (for example TSH 20–50 mIU/L with low free T4), the recommendation is:
1. Start levothyroxine immediately.
2. Monitor TSH and free T4 every 4–6 weeks.
3. Continue routine fetal surveillance.
The presence of hypothyroidism alone would not warrant recommending termination, even if it was present during organogenesis.
• TSH does not cross the placenta to any significant extent.
• The fetus eventually develops its own hypothalamic-pituitary-thyroid axis.
• Fetal thyroid hormone is produced locally by the fetal thyroid gland.
By 5–6 weeks:
• Neural tube closure has occurred.
• Primary brain vesicles have formed.
By 8–10 weeks:
• Rapid neuronal proliferation is underway.
• Early neuronal migration has begun.
• Cortical organization is being established.
By 10–12 weeks:
• Multiple thyroid hormone receptors are already present in the fetal brain.
• Genes regulated by thyroid hormone are active.
The fetal brain is still tiny, but many developmental processes are occurring that influence later brain architecture.
The key issue is timing.
Before the fetal thyroid functions
The fetal thyroid begins concentrating iodine around 10–12 weeks and becomes progressively functional around 12–14 weeks.
Before that, the fetal brain relies heavily on maternal T4 crossing the placenta.
Maternal T4 is converted within fetal tissues by deiodinases:
• T4 → T3 locally in the fetal brain
• T3 then regulates neuronal proliferation, migration, differentiation, synaptogenesis, and myelination
So the concern is not maternal TSH crossing the placenta. The concern is that high maternal TSH reflects inadequate maternal T4 availability.
